We are live on ! Find out more
SGMT icon

Sagimet Biosciences
SGMT

51 hedge funds and large institutions have $76.2M invested in Sagimet Biosciences in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 9

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

6% more funds holding

Funds holding: 48 → 51 (+3)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5.26% less ownership

Funds ownership: 72.88% → 67.62% (-5.3%)

41% less capital invested

Capital invested by funds: $130M → $76.2M (-$54M)

Holders
51
Holders Change
+3
Holders Change %
+6.25%
% of All Funds
0.74%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
17
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$3.02M
2
BOCH
Blue Owl Capital Holdings
New York
+$1.68M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.16M
4
BlackRock
BlackRock
New York
+$302K
5
State Street
State Street
Massachusetts
+$236K

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$4.53M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.54M
3
RI
RTW Investments
New York
-$3.52M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.74M
5
PIM
Platinum Investment Management
Australia
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$18.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$10.4M -$3.54M -750,299 -28%
BBA
3
Baker Bros. Advisors
New York
$7.89M +$3.02M +641,159 +79%
HA
4
HHLR Advisors
Cayman Islands
$7.86M – – –
AG
5
Artal Group
Luxembourg
$5.01M – – –
RSCM
6
Rock Springs Capital Management
Maryland
$4M – – –
PHS
7
PFM Health Sciences
California
$3.67M – – –
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$2.64M +$1.16M +246,531 +103%
ACM
9
Altium Capital Management
New York
$2.53M – – –
BlackRock
10
BlackRock
New York
$2.1M +$302K +63,993 +20%
BOCH
11
Blue Owl Capital Holdings
New York
$1.93M +$1.68M +355,377 New
WP
12
Woodline Partners
California
$1.63M -$9 -2 -0%
Vanguard Group
13
Vanguard Group
Pennsylvania
$1.33M -$4.39K -930 -0.4%
DI
14
DUMAC Inc
North Carolina
$1.11M – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$655K +$47.5K +10,075 +9%
PIM
16
Platinum Investment Management
Australia
$606K -$1.28M -272,161 -71%
Federated Hermes
17
Federated Hermes
Pennsylvania
$527K +$90.9K +19,276 +25%
State Street
18
State Street
Massachusetts
$437K +$236K +50,076 +164%
GCM
19
Ghisallo Capital Management
Massachusetts
$325K – – –
YF
20
Yu Fan
$310K – – –
Victory Capital Management
21
Victory Capital Management
Texas
$307K +$182K +38,610 +215%
Millennium Management
22
Millennium Management
New York
$260K +$169K +35,820 +293%
Northern Trust
23
Northern Trust
Illinois
$254K +$23.1K +4,892 +12%
BCM
24
Bridgeway Capital Management
Texas
$244K +$212K +45,000 New
Two Sigma Investments
25
Two Sigma Investments
New York
$238K +$207K +43,900 New
1
2 3

SGMT Hedge Fund Activity: Q4 2023 in Review

51 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q4 2023, worth a combined $76.2M — down 41% from $130M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new SGMT positions and 7 closed out — a net gain of 4 holders — while 17 added to existing stakes and 9 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $3.02M. The largest seller was VR Adviser, exiting entirely with an estimated $4.53M sold.

  • 51 institutional investors held Sagimet Biosciences (SGMT) as of Q4 2023, up from 48 in Q3 2023.
  • Funds reported $76.2M of Sagimet Biosciences stock for Q4 2023, down 41% quarter-over-quarter.
  • 11 funds opened new Sagimet Biosciences positions in Q4 2023 and 7 closed out, a net change of +4 holders.
  • The largest Sagimet Biosciences buyer in Q4 2023 was Baker Bros. Advisors, an estimated $3.02M added.
  • The largest Sagimet Biosciences seller in Q4 2023 was VR Adviser, an estimated $4.53M sold.

Based on aggregated 13F filings for Q4 2023.